Drug News

FDA Halts Cancer Drug Trial After The Death of 2 Patient

According to, EndPoints News the FDA has handed Gossamer Bio, a biotech company, a partial clinical hold after two patients died in its BTK inhibitor trial. The hold was placed on the oral lymphoma drug trial after serious adverse events, including atrial fibrillation, a sudden death event, and a fatal intracranial hemorrhage, according to a  Securities and Exchange Commission filing.

The death event and fatal hemorrhage occurred in two different patients with central nervous system lymphoma, Bryan Giraudo, finance, and operating chief, told Endpoints News. Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The biotech company is terminating all studies and development of the drug at this time, according to the report


Dr. Oche Otorkpa PG Cert, MPH, PhD

Dr. Oche is a seasoned Public Health specialist who holds a post graduate certificate in Pharmacology and Therapeutics, an MPH, and a PhD both from Texila American University. He is a member of the International Society of Substance Use Professionals and a Fellow of the Royal Society for Public Health in the UK. He authored two books: "The Unseen Terrorist," published by AuthorHouse UK, and "The Night Before I Killed Addiction."

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker